Effects of liraglutide on left ventricular function in patients with non-ST-segment elevation myocardial infarction

Endocrine

Volumn 52, Issue 3, 2016, Pages 516-526

  Chen, Wei Ren ^a   Shen, Xue Qin ^a   Zhang, Ying ^a   Chen, Yun Dai ^a   Hu, Shun Ying ^a   Qian, Geng ^a   Wang, Jing ^a   Yang, Jun Jie ^a   Wang, Zhi Feng ^a   Tian, Feng ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Congestive heart failure; Glucagon like peptide 1; Left ventricular ejection fraction; Metabolism; Non ST segment elevation myocardial infarction

Indexed keywords

C REACTIVE PROTEIN; GLYCOSYLATED HEMOGLOBIN; INTERLEUKIN 6; LIPID; LIRAGLUTIDE; MALONALDEHYDE; PLACEBO; SUPEROXIDE DISMUTASE;

ADULT; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG RESPONSE; DRUG SAFETY; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NAUSEA; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OXIDATIVE STRESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT OUTCOME; AGED; BLOOD; DIAGNOSTIC IMAGING; DRUG EFFECTS; ECHOCARDIOGRAPHY; METABOLISM; NON-ST ELEVATED MYOCARDIAL INFARCTION; PATHOPHYSIOLOGY; PHYSIOLOGY;

AGED; C-REACTIVE PROTEIN; DOUBLE-BLIND METHOD; ECHOCARDIOGRAPHY; FEMALE; HUMANS; LIPIDS; LIRAGLUTIDE; MALE; MIDDLE AGED; NON-ST ELEVATED MYOCARDIAL INFARCTION; OXIDATIVE STRESS; PLACEBOS; VENTRICULAR FUNCTION, LEFT;

EID: 84947080292     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-015-0798-0     Document Type: Article

References (36)

1. G. Montalescot, L. Bolognese, D. Dudek, P. Goldstein, C. Hamm, J.F. Tanguay, J.M. ten Berg, D.L. Miller, T.M. Costigan, J. Goedicke, J. Silvain, P. Angioli, J. Legutko, M. Niethammer, Z. Motovska, J.A. Jakubowski, G. Cayla, L.O. Visconti, E. Vicaut, P. Widimsky, Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N. Engl. J. Med. 369(11), 999–1010 (2013)
2. D. Aronson, H. Hammerman, M.R. Kapeliovich, A. Suleiman, Y. Agmon, R. Beyar, W. Markiewicz, M. Suleiman, Fasting glucose in acute myocardial infarction: incremental value for long-term mortality and relationship with left ventricular systolic function. Diabetes Care 30(4), 960–966 (2007)
3. J. Lønborg, N. Vejlstrup, H. Kelbæk, H.E. Bøtker, W.Y. Kim, A.B. Mathiasen, E. Jørgensen, S. Helqvist, K. Saunamäki, P. Clemmensen, L. Holmvang, L. Thuesen, L.R. Krusell, J.S. Jensen, L. Køber, M. Treiman, J.J. Holst, T. Engstrøm, Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur. Heart J. 33(12), 1491–1499 (2012)
4. A. Ceriello, A. Novials, E. Ortega, S. Canivell, L. La Sala, G. Pujadas, K. Esposito, D. Giugliano, S. Genovese, Glucagon-like peptide 1 reduces endothelial dysfunction, inflammation, and oxidative stress induced by both hyperglycemia and hypoglycemia in type 1 diabetes. Diabetes Care 36(8), 2346–2350 (2013)
5. L.A. Nikolaidis, A. Doverspike, T. Hentosz, L. Zourelias, Y.T. Shen, D. Elahi, R.P. Shannon, Glucagon-like peptide-1 limits myocardial stunning following brief coronary occlusion and reperfusion in conscious canines. J. Pharmacol. Exp. Ther. 312(1), 303–308 (2005)
6. L.A. Nikolaidis, D. Elahi, T. Hentosz, A. Doverspike, R. Huerbin, L. Zourelias, C. Stolarski, Y.T. Shen, R.P. Shannon, Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 110(8), 955–961 (2004)
7. M.H. Noyan-Ashraf, M.A. Momen, K. Ban, A.M. Sadi, Y.Q. Zhou, A.M. Riazi, L.L. Baggio, R.M. Henkelman, M. Husain, D.J. Drucker, GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 58(4), 975–983 (2009)
8. L.A. Nikolaidis, S. Mankad, G.G. Sokos, G. Miske, A. Shah, D. Elahi, R.P. Shannon, Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 109(8), 962–965 (2004)
9. K. Thygesen, J.S. Alpert, A.S. Jaffe, M.L. Simoons, B.R. Chaitman, H.D. White, Writing Group on the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction; ESC Committee for Practice Guidelines (CPG). Third universal definition of myocardial infarction. Eur. Heart J. 33(20), 2551–2567 (2012)
10. Workgroup on Hypoglycemia, American Diabetes Association, Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 28(5), 1245–1249 (2005)
11. A.S. Levey, L.A. Stevens, C.H. Schmid, Y.L. Zhang, A.F. Castro 3rd, H.I. Feldman, J.W. Kusek, P. Eggers, Lente F. Van, T. Greene, J. Coresh, CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A New Equation to Estimate Glomerular Filtration Rate. Ann. Intern. Med. 150(9), 604–612 (2009)
12. P.J. Best, D.N. Reddan, P.B. Berger, L.A. Szczech, P.A. McCullough, R.M. Califf, Cardiovascular disease and chronic kidney disease: insights and an update. Am. Heart J. 148(2), 230–242 (2004)
13. W.L. Miller, R.S. Wright, J.P. Grill, S.L. Kopecky, Improved survival after acute myocardial infarction in patients with advanced Killip class. Clin. Cardiol. 23(10), 751–758 (2000)
14. M. Parks, C. Rosebraugh, Weighing risks and benefits of liraglutide–the FDA’s review of a new antidiabetic therapy. N. Engl. J. Med. 362(9), 774–777 (2010)
15. A. Ganau, R.B. Devereux, M.J. Roman, G. de Simone, T.G. Pickering, P.S. Saba, P. Vargiu, I. Simongini, J.H. Laragh, Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J. Am. Coll. Cardiol. 19(7), 1550–1558 (1992)
16. G.A. Oswald, S. Corcoran, J.S. Yudkin, Prevalence and risks of hyperglycaemia and undiagnosed diabetes in patients with acute myocardial infarction. Lancet 1(8389), 1264–1267 (1984)
17. R. Marfella, M. Siniscalchi, K. Esposito, A. Sellitto, U. De Fanis, C. Romano, M. Portoghese, S. Siciliano, F. Nappo, F.C. Sasso, N. Mininni, F. Cacciapuoti, G. Lucivero, R. Giunta, M. Verza, D. Giugliano, Effects of stress hyperglycemia on acute myocardial infarction: role of inflammatory immune process in functional cardiac outcome. Diabetes Care 26(11), 3129–3135 (2003)
18. K. Tanaka, Y. Saisho, T. Kawai, M. Tanaka, S. Meguro, J. Irie, T. Imai, T. Shigihara, J. Morimoto, K. Yajima, Y. Atsumi, I. Takei, H. Itoh, Efficacy and safety of liraglutide monotherapy compared with metformin in Japanese overweight/obese patients with type 2 diabetes. Endocr. J. 62(5), 399–409 (2015)
19. A. Shiraki, J. Oyama, H. Komoda, M. Asaka, A. Komatsu, M. Sakuma, K. Kodama, Y. Sakamoto, N. Kotooka, T. Hirase, K. Node, The glucagon-like peptide 1 analog liraglutide reduces TNF-α-induced oxidative stress and inflammation in endothelial cells. Atherosclerosis 221(2), 375–382 (2012)
20. B.B. Dokken, L.R. La Bonte, G. Davis-Gorman, M.K. Teachey, N. Seaver, P.F. McDonagh, Glucagon-like peptide-1 (GLP-1), immediately prior to reperfusion, decreases neutrophil activation and reduces myocardial infarct size in rodents. Horm. Metab. Res. 43(5), 300–305 (2011)
21. J. Wichmann, M. Ketzel, T. Ellermann, S. Loft, Apparent temperature and acute myocardial infarction hospital admissions in Copenhagen, Denmark: a case-crossover study. Environ. Health 11, 19 (2012)
22. R. Ferrari, E. Merli, G. Cicchitelli, D. Mele, A. Fucili, C. Ceconi, Therapeutic effects of l-carnitine and propionyl-l-carnitine on cardiovascular diseases: a review. Ann. N. Y. Acad. Sci. 1033, 79–91 (2004)
23. N.B. Perepech, A.O. Nedoshivin, I.V. Nesterova, Neoton and thrombolytic therapy of myocardial infarction. Ter. Arkh. 73(9), 50–55 (2001)
24. M. Marre, J. Shaw, M. Brändle, W.M. Bebakar, N.A. Kamaruddin, J. Strand, M. Zdravkovic, T.D. Le Thi, S. Colagiuri, Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight con-trol compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet. Med. 26(3), 268–278 (2009)
25. J. Lønborg, H. Kelbæk, N. Vejlstrup, H.E. Bøtker, W.Y. Kim, L. Holmvang, E. Jørgensen, S. Helqvist, K. Saunamäki, C.J. Terkelsen, M.M. Schoos, L. Køber, P. Clemmensen, M. Treiman, T. Engstrøm, Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia. Circulation 5(2), 288–295 (2012)
26. J.S. Woo, W. Kim, S.J. Ha, J.B. Kim, S.J. Kim, W.S. Kim, H.J. Seon, K.S. Kim, Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study. Arterioscler. Thromb. Vasc. Biol. 33(9), 2252–2260 (2013)
27. L.M. McCormick, A.C. Kydd, P.A. Read, L.S. Ring, S.J. Bond, S.P. Hoole, D.P. Dutka, Chronic dipeptidyl peptidase-4 inhibition with sitagliptin is associated with sustained protection against ischemic left ventricular dysfunction in a pilot study of patients with type 2 diabetes mellitus and coronary artery disease. Circulation 7(2), 274–281 (2014)
28. B. Zinman, J. Gerich, J.B. Buse, A. Lewin, S. Schwartz, P. Raskin, P.M. Hale, M. Zdravkovic, L. Blonde, LEAD-4 Study Investigators. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met + TZD). Diabetes Care 32(7), 1224–1230 (2009)
29. L.E. Robinson, T.A. Holt, K. Rees, H.S. Randeva, J.P. O’Hare, Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. BMJ Open 3(1), e001986 (2013)
30. P.M. Okin, S.E. Kjeldsen, S. Julius, D.A. Hille, B. Dahlöf, J.M. Edelman, R.B. Devereux, All-cause and cardiovascular mortality in relation to changing heart rate during treatment of hypertensive patients with electrocardiographic left ventricular hypertrophy. Eur. Heart J. 31(18), 2271–2279 (2010)
31. T. Nozue, M. Yamada, T. Tsunoda, H. Katoh, S. Ito, T. Iwaki, I. Michishita, Effects of liraglutide, a glucagon-like peptide-1 analog, on left ventricular remodeling assessed by cardiac magnetic resonance imaging in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Heart Vessel. (2015). doi:10.1007/s00380-015-0734-5
32. A. Undas, I. Wiek, E. Stêpien, K. Zmudka, W. Tracz, Hyperglycemia is associated with enhanced thrombin formation, platelet activation, and fibrin clot resistance to lysis in patients with acute coronary syndrome. Diabetes Care 31(8), 1590–1595 (2008)
33. J.Y. Park, N. Takahara, A. Gabriele, E. Chou, K. Naruse, K. Suzuma, T. Yamauchi, S.W. Ha, M. Meier, C.J. Rhodes, G.L. King, Induction of endothelin-1 expression by glucose: an effect of protein kinase C activation. Diabetes 49(7), 1239–1248 (2000)
34. T. Zhao, P. Parikh, S. Bhashyam, H. Bolukoglu, I. Poornima, Y.T. Shen, R.P. Shannon, Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J. Pharmacol. Exp. Ther. 317(3), 1106–1113 (2006)
35. E. Osto, P. Doytcheva, C. Corteville, M. Bueter, C. Dörig, S. Stivala, H. Buhmann, S. Colin, L. Rohrer, R. Hasballa, A. Tailleux, C. Wolfrum, F. Tona, J. Manz, D. Vetter, K. Spliethoff, P.M. Vanhoutte, U. Landmesser, F. Pattou, B. Staels, C.M. Matter, T.A. Lutz, T.F. Lüscher, Rapid and body weight-independent improvement of endothelial and high-density lipoprotein function after Roux-en-Y gastric bypass: role of glucagon-like peptide-1. Circulation 131(10), 871–881 (2015)
36. T. Heitzer, T. Schlinzig, K. Krohn, T. Meinertz, T. Münzel, Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 104(22), 2673–2678 (2001)